{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(1)"],"submitter":["Berning P"],"pubmed_abstract":["Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles are challenged by CAR-T-cells and other immunotherapies. We examined the transplantation trends and outcomes for DLBCL patients undergoing auto-/allo-HSCT between 1990 and 2021 reported to EBMT. Over this period, 41,148 patients underwent auto-HSCT, peaking at 1911 cases in 2016, while allo-HSCT saw a maximum of 294 cases in 2018. The recent decline in transplants corresponds to increased CAR-T treatments (1117 cases in 2021). Median age for auto-HSCT rose from 42 (1990-1994) to 58 years (2015-2021), with peripheral blood becoming the primary stem cell source post-1994. Allo-HSCT median age increased fr"],"journal":["Blood cancer journal"],"pagination":["106"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11226679"],"repository":["biostudies-literature"],"pubmed_title":["Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years."],"pmcid":["PMC11226679"],"pubmed_authors":["Nguyen Quoc S","Schmitz N","Blau IW","Huynh A","Galimard JE","Castilla-Llorente C","Goldstone AH","Rosler W","Capria S","Broers AEC","Glass B","Fekom M","Sureda A","Ngoya M","Bittenbring J","Chevallier P","Shumilov E","Berning P","Finel H","Dreger P","Meijer E","Trneny M","Caillot D","Ghesquieres H","Thieblemont C","Carpenter B","Forcade E","Blaise D","Nagler A","Montoto S","Strussmann T"],"additional_accession":[]},"is_claimable":false,"name":"Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years.","description":"Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles are challenged by CAR-T-cells and other immunotherapies. We examined the transplantation trends and outcomes for DLBCL patients undergoing auto-/allo-HSCT between 1990 and 2021 reported to EBMT. Over this period, 41,148 patients underwent auto-HSCT, peaking at 1911 cases in 2016, while allo-HSCT saw a maximum of 294 cases in 2018. The recent decline in transplants corresponds to increased CAR-T treatments (1117 cases in 2021). Median age for auto-HSCT rose from 42 (1990-1994) to 58 years (2015-2021), with peripheral blood becoming the primary stem cell source post-1994. Allo-HSCT median age increased fr","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-22T15:31:35.94Z","creation":"2025-04-06T01:22:54.555Z"},"accession":"S-EPMC11226679","cross_references":{"pubmed":["38969655"],"doi":["10.1038/s41408-024-01085-9"]}}